Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey

被引:5
作者
Aksu, Tekin [1 ]
Fettah, Ali [1 ]
Bozkaya, Ikbal Ok [1 ]
Bastemur, Mehmet [1 ]
Kara, Abdurrahman [1 ]
Culha, Vildan Kosan [1 ]
Ozbek, Namik Yasar [1 ]
Yarali, Nese [1 ]
机构
[1] Univ Hlth Sci, Ankara Child Hlth & Dis Hematol Oncol Training &, Pediat Hematol & Oncol, Ankara, Turkey
关键词
Acute promyelocytic leukemia; Hypogranular variant APL; ATRA toxicity; AGENT ARSENIC TRIOXIDE; ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; ATRA; CLASSIFICATION; CONSOLIDATION; ADOLESCENTS; INDUCTION; DIAGNOSIS; PROTOCOL;
D O I
10.4084/MJHID.2018.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Acute promyelocytic leukemia (APL), is a distinct subtype of acute myeloid leukemia (AML) characterized by a tendency to hemorrhage and excellent response to all-trans retinoic acid (ATRA). In this retrospective study, we aimed to determine the incidence, clinical symptoms, toxicities, and outcome of children with APL in our center.Methods: We retrospectively reviewed the medical records of children (age < 18 years) diagnosed with APL in our pediatric hematology department between January 2006-December 2016. Results: Pediatric APL represents 20.5% of AML cases in this cohort. Most of the cases presented as classical M3, albeit hypogranular variant was described in 12% of the cohort. Patients with hypogranular variant APL were differed from classical APL by co-expression of CD2 and CD34. About 3/4 of APL patients had hemorrhagic findings at admission or the induction treatment. Severe bleeding manifested as intracranial hemorrhage was present in three patients and intracranial arterial thrombosis was present in one. Six patients showed side effects of ATRA such as pseudotumor cerebri, differentiation syndrome resulting in dilated cardiomyopathy, and pulmonary infiltrates. Five-year overall survival (OS) and early death rate were found to be 82.5% and 12% respectively. Conclusions: A high frequency (20.5%) of APL was noted among children with AML in this single-center study. The overall mortality rate was 17.5%. Since the induction death rate was 12% and life-threatening bleeding was the primary problem, awareness and urgent treatment are critical factors to reduce early losses.
引用
收藏
页数:7
相关论文
共 31 条
  • [1] Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy
    Abla, Oussama
    Ribeiro, Raul C.
    Testi, Anna Maria
    Montesinos, Pau
    Creutzig, Ursula
    Sung, Lillian
    Di Giuseppe, Giancarlo
    Stephens, Derek
    Feusner, James H.
    Powell, Bayard L.
    Hasle, Henrik
    Kaspers, Gertjan J. L.
    Dalla-Pozza, Luciano
    Lassaletta, Alvaro
    Tallman, Martin S.
    Locatelli, Franco
    Reinhardt, Dirk
    Lo-Coco, Francesco
    Hitzler, Johann
    Sanz, Miguel A.
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 (09) : 1449 - 1456
  • [2] How I treat children and adolescents with acute promyelocytic leukaemia
    Abla, Oussama
    Ribeiro, Raul C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) : 24 - 38
  • [3] Albano F, 2006, HAEMATOLOGICA, V91, P311
  • [4] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
  • [5] Differentiating agents in pediatric malignancies: All-trans-retinoic acid and arsenic in acute promyelocytic leukemia
    Calleja E.M.
    Warrell R.P.
    Jr
    [J]. Current Oncology Reports, 2000, 2 (6) : 519 - 523
  • [6] REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA
    CHESON, BD
    CASSILETH, PA
    HEAD, DR
    SCHIFFER, CA
    BENNETT, JM
    BLOOMFIELD, CD
    BRUNNING, R
    GALE, RP
    GREVER, MR
    KEATING, MJ
    SAWITSKY, A
    STASS, S
    WEINSTEIN, H
    WOODS, WG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) : 813 - 819
  • [7] Current management of newly diagnosed acute promyelocytic leukemia
    Cicconi, L.
    Lo-Coco, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (08) : 1474 - 1481
  • [8] Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria
    Coombs, Catherine C.
    DeAngelis, Lisa M.
    Feusner, James H.
    Rowe, Jacob M.
    Tallman, Martin S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03) : 146 - 151
  • [9] Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
    Creutzig, Ursula
    Zimmermann, Martin
    Bourquin, Jean-Pierre
    Dworzak, Michael N.
    Fleischhack, Gudrun
    Graf, Norbert
    Klingebiel, Thomas
    Kremens, Bernhard
    Lehrnbecher, Thomas
    von Neuhoff, Christine
    Ritter, Joerg
    Sander, Annette
    Schrauder, Andre
    von Stackelberg, Arend
    Stary, Jan
    Reinhardt, Dirk
    [J]. BLOOD, 2013, 122 (01) : 37 - 43
  • [10] Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses
    Creutzig, Ursula
    Zimmermann, Martin
    Dworzak, Michael
    Urban, Christian
    Henze, Guenter
    Kremens, Bernhard
    Lakomek, Max
    Bourquin, Jean-Pierre
    Stary, Jan
    Reinhardt, Dirk
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) : 399 - 409